These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 10218512)

  • 1. Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    Williams GM
    J Natl Cancer Inst; 1999 Apr; 91(8):722-3. PubMed ID: 10218512
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    Mäenpää J; Ellmén J; Pasanen T; Kaukonen M
    J Natl Cancer Inst; 1999 Jun; 91(11):972-3. PubMed ID: 10359551
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    DeGregorio MW
    J Natl Cancer Inst; 1999 Mar; 91(5):474-5. PubMed ID: 10070949
    [No Abstract]   [Full Text] [Related]  

  • 4. Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.
    O'Regan RM; Cisneros A; England GM; MacGregor JI; Muenzner HD; Assikis VJ; Bilimoria MM; Piette M; Dragan YP; Pitot HC; Chatterton R; Jordan VC
    J Natl Cancer Inst; 1998 Oct; 90(20):1552-8. PubMed ID: 9790548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in toxicity findings for antiestrogens.
    Williams GM
    J Clin Oncol; 1998 May; 16(5):1999-2000. PubMed ID: 9586922
    [No Abstract]   [Full Text] [Related]  

  • 6. Toxicity of antiestrogens.
    Hirsimäki P; Aaltonen A; Mäntylä E
    Breast J; 2002; 8(2):92-6. PubMed ID: 11896754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiestrogen therapy: uncertainties and risk assessment.
    Smith LL; White IN
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):14-22. PubMed ID: 9556786
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tamoxifen and the endometrium.
    Barakat RR
    Cancer Treat Res; 1998; 94():195-207. PubMed ID: 9587689
    [No Abstract]   [Full Text] [Related]  

  • 9. [Tamoxifen and breast cancer: is everything known already?].
    Marchetti P; Porzio G; Trapasso T; Baldi PL; Ficorella C
    Tumori; 1998; 84(6):A1-5. PubMed ID: 10080686
    [No Abstract]   [Full Text] [Related]  

  • 10. Endometrial cancers from tamoxifen are not more aggressive.
    Ziegler J
    J Natl Cancer Inst; 1996 Aug; 88(16):1101. PubMed ID: 8757186
    [No Abstract]   [Full Text] [Related]  

  • 11. Tamoxifen and toremifene treatment of breast cancer and risk of subsequent endometrial cancer: a population-based case-control study.
    Pukkala E; Kyyrönen P; Sankila R; Holli K
    Int J Cancer; 2002 Jul; 100(3):337-41. PubMed ID: 12115550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Should tamoxifen users be screened for endometrial lesions?
    Neven P; Vergote I
    Lancet; 1998 Jan; 351(9097):155-7. PubMed ID: 9449866
    [No Abstract]   [Full Text] [Related]  

  • 13. Postmenopausal HRT--a role for a safe antioestrogen.
    Williams GM
    Int J Clin Pract; 1998; 52(1):5. PubMed ID: 9536558
    [No Abstract]   [Full Text] [Related]  

  • 14. [Tamoxifen and endometrial cancer. A case report].
    Orbo A; Lindal S; Mortensen E
    Tidsskr Nor Laegeforen; 1996 Jun; 116(16):1877-8. PubMed ID: 8711699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormone therapy for breast cancer, with an emphasis on the pure antiestrogen fulvestrant: mode of action, antitumor efficacy and effects on bone health.
    Journé F; Body JJ; Leclercq G; Laurent G
    Expert Opin Drug Saf; 2008 May; 7(3):241-58. PubMed ID: 18462183
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blockade of the stimulatory effect of estrogens, OH-tamoxifen, OH-toremifene, droloxifene, and raloxifene on alkaline phosphatase activity by the antiestrogen EM-800 in human endometrial adenocarcinoma Ishikawa cells.
    Simard J; Sanchez R; Poirier D; Gauthier S; Singh SM; Merand Y; Belanger A; Labrie C; Labrie F
    Cancer Res; 1997 Aug; 57(16):3494-7. PubMed ID: 9270018
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The duration of adjuvant tamoxifen therapy.
    Bilimoria MM; Jordan VC
    Cancer Treat Res; 1998; 94():181-93. PubMed ID: 9587688
    [No Abstract]   [Full Text] [Related]  

  • 18. Status of antiestrogen breast cancer prevention trials.
    Powles TJ
    Oncology (Williston Park); 1998 Mar; 12(3 Suppl 5):28-31. PubMed ID: 9556788
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re: second cancers after adjuvant tamoxifen therapy for breast cancer.
    Rutqvist LE
    J Natl Cancer Inst; 1996 Oct; 88(20):1497-9; author reply, 1497-9. PubMed ID: 8841030
    [No Abstract]   [Full Text] [Related]  

  • 20. Gynaecological aspects of tamoxifen treatment in breast cancer patients.
    Obwegeser R; Auerbach L; Kubista E
    Cancer Treat Rev; 1997; 23(5-6):289-304. PubMed ID: 9465881
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.